Baltimore, MD 的 三陰性乳癌 臨床試驗
12 項針對 三陰性乳癌 的研究正在 Baltimore（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
招募中3 期
- MedStar Franklin Square Medical Center ( Site 0031), Baltimore
- MedStar Good Samaritan Hospital ( Site 0079), Baltimore
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
招募中3 期
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
招募中2 期
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
招募中1 期
- United Theranostics, Glen Burnie · 距離 9 英里
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
招募中2 期
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- Sinai Hospital of Baltimore, Inc., Baltimore
- St. Agnes Hospital, Baltimore
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
- 還有 1 項
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
招募中2 期
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Local Institution - 1035, Baltimore
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
招募中1 期
- United Theranostics, Glen Burnie · 距離 9 英里
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
招募中1/2 期
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
招募中2 期
- University of Maryland Medical Center (UMMC), Baltimore
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
招募中1 期
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
其他城市的 三陰性乳癌 試驗
- Houston, TX42 項研究
- New York City, NY31 項研究
- Nashville, TN28 項研究
- Los Angeles, CA27 項研究
- Boston, MA26 項研究
- San Antonio, TX23 項研究
- St. Louis, MO21 項研究
- Arlington, VA20 項研究
- Atlanta, GA20 項研究
- Dallas, TX18 項研究
- Chicago, IL16 項研究
- Columbus, OH16 項研究
Baltimore 的其他研究
- 非小細胞肺癌60 項研究
- 乳癌47 項研究
- 前列腺癌43 項研究
- 肺癌40 項研究
- 癌症（所有類型）37 項研究
- 胰臟癌31 項研究
- 大腸直腸癌31 項研究
- 轉移性癌症28 項研究
- 肥胖症26 項研究
- 膀胱癌24 項研究
- 心臟衰竭24 項研究
- 卵巢癌22 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。